First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies-Reference-Cited by-同舟云学术

First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies

Published:2015-01-19 Issue:4 Volume:16 Page:465-472
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Morikawa Naoto,Minegishi Yuji,Inoue Akira,Maemondo Makoto,Kobayashi Kunihiko,Sugawara Shunichi,Harada Masao,Hagiwara Koichi,Okinaga Shoji,Oizumi Satoshi,Nukiwa Toshihiro,Gemma Akihiko

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1002396

Reference21 articles.

1. Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

5. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world study of first-line therapy with aumolertinib for elderly patients with non‑small cell lung cancer harboring EGFR mutation;2024-01-22

2. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP);Lung Cancer;2023-12

3. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-07-06

4. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2023-04

5. Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF);Cancers;2022-02-02